Anti-CGRP Migraine Antibodies Work Outside the Brain, Not Inside It
Four FDA-approved anti-CGRP antibodies for migraine likely work by targeting peripheral nerve signaling rather than crossing into the brain.
Quick Facts
What This Study Found
The review analyzes evidence on four FDA-approved anti-CGRP monoclonal antibodies: erenumab, fremanezumab, galcanezumab, and eptinezumab. All target either CGRP itself or its receptor in the trigeminovascular system.
The central question is whether these antibodies work inside the brain or outside it. At roughly 150 kDa (150,000 daltons), these molecules are far too large to cross an intact blood-brain barrier (BBB). Multiple studies confirm minimal BBB penetration.
The evidence points to peripheral mechanisms: the antibodies likely block CGRP signaling at sensory nerve endings in the meninges (brain coverings), at the trigeminal ganglion (a nerve cluster outside the BBB), and in peripheral blood vessels. Some researchers have suggested the antibodies might access areas where the BBB is leaky, such as the area postrema, but this remains debated.
Key Numbers
4 FDA-approved mAbs; ~150 kDa molecular weight; gepant development interrupted by pharmacokinetic issues
How They Did This
This is a narrative review summarizing published research on the pharmacology, pharmacokinetics, and mechanisms of action of anti-CGRP monoclonal antibodies. It draws from randomized clinical trials, preclinical animal studies, and pharmacokinetic analyses.
Why This Research Matters
Understanding where these drugs work matters for developing better versions. If peripheral action is sufficient, future migraine drugs do not need to cross the blood-brain barrier at all. This simplifies drug design and may reduce side effects. It also helps explain why these antibodies have remarkably clean safety profiles compared to older migraine drugs that act centrally.
The Bigger Picture
Understanding that peripheral CGRP blockade is sufficient for migraine prevention simplifies future drug development. Designers do not need to engineer molecules that cross the blood-brain barrier, opening the door to safer, more accessible migraine treatments.
What This Study Doesn't Tell Us
As a narrative review, this paper selects and interprets existing evidence rather than generating new data. The question of BBB penetration is not fully settled; some evidence suggests partial BBB disruption during migraine attacks could allow limited antibody access. The review also cannot address long-term effects of blocking peripheral CGRP signaling.
Questions This Raises
- ?Could partial BBB penetration contribute to efficacy in some patients?
- ?Why do some migraine patients not respond to anti-CGRP therapy?
- ?Will smaller CGRP-blocking molecules with central access prove more effective?
Trust & Context
- Key Stat:
- 4 approved drugs target CGRP or its receptor peripherally, avoiding the need to cross the blood-brain barrier
- Evidence Grade:
- Strong evidence. Based on clinical trial results and pharmacokinetic data from multiple FDA-approved drugs, synthesized in a comprehensive narrative review.
- Study Age:
- Published in 2020. The anti-CGRP drug class has expanded since, with additional oral CGRP antagonists (gepants) now available.
- Original Title:
- The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms.
- Published In:
- CNS & neurological disorders drug targets, 19(5), 344-359 (2020)
- Authors:
- González-Hernández, Abimael(3), Marichal-Cancino, Bruno A(2), García-Boll, Enrique, Villalón, Carlos M
- Database ID:
- RPEP-04822
Evidence Hierarchy
Frequently Asked Questions
If these drugs can't enter the brain, how do they stop migraines?
They block CGRP signaling at nerve endings and blood vessels outside the brain. This prevents the pain signals from being transmitted centrally, stopping migraines before they start.
Are anti-CGRP antibodies better than older migraine preventives?
They have fewer side effects than older drugs like topiramate or beta-blockers, and they specifically target migraine biology rather than broadly affecting the nervous system.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04822APA
González-Hernández, Abimael; Marichal-Cancino, Bruno A; García-Boll, Enrique; Villalón, Carlos M. (2020). The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms.. CNS & neurological disorders drug targets, 19(5), 344-359. https://doi.org/10.2174/1871527319666200618144637
MLA
González-Hernández, Abimael, et al. "The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms.." CNS & neurological disorders drug targets, 2020. https://doi.org/10.2174/1871527319666200618144637
RethinkPeptides
RethinkPeptides Research Database. "The locus of Action of CGRPergic Monoclonal Antibodies Again..." RPEP-04822. Retrieved from https://rethinkpeptides.com/research/gonzalez-hernandez-2020-the-locus-of-action
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.